Display options
Cite
Espandar G, Moghimi J, Ghorbani R, et al. Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study. Med Hypothesis Discov Innov Ophthalmol. 2016;5(2):41-46
Espandar, G., Moghimi, J., Ghorbani, R., Pourazizi, M., Seiri, M. A., & Khosravi, S. (2016). Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study. Medical hypothesis, discovery & innovation ophthalmology journal, 5(2), 41-46.
Espandar, Goldis, et al. "Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study." Medical hypothesis, discovery & innovation ophthalmology journal vol. 5,2 (2016): 41-46.
Espandar G, Moghimi J, Ghorbani R, Pourazizi M, Seiri MA, Khosravi S. Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study. Med Hypothesis Discov Innov Ophthalmol. 2016;5(2):41-46. PMID: 28293646; PMCID: PMC5347188.
Copy Download .nbib Format: NLM
Share it on

Med Hypothesis Discov Innov Ophthalmol. 2016;5(2):41-46.

Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study.

Medical hypothesis, discovery & innovation ophthalmology journal

Goldis Espandar, Jamileh Moghimi, Raheb Ghorbani, Mohsen Pourazizi, Mohammad-Ali Seiri, Shervin Khosravi

Affiliations

  1. 1 Department of Ophthalmology, Semnan University of Medical Sciences, Semnan, Iran ; 2 Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  2. 3 Department of Internal Medicine, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
  3. 4 Research Center of Health Social Determinants, Semnan University of Medical Sciences, Semnan, Iran.
  4. 5 Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
  5. 6 Students' Research Committee, Semnan University of Medical Sciences, Semnan, Iran.

PMID: 28293646 PMCID: PMC5347188

Abstract

Hydroxychloroquine (HCQ) is an antimalarial medication that can also be used to treat autoimmune diseases. However, it can produce irreversible changes to the retina that lead to visual impairment. The aim of this study was to determine the proportion of patients treated with HCQ who develop retinal toxicity and the risk factors for the development of HCQ-induced retinal toxicity among Iranian patients. The is a cross-sectional clinical study of 59 patients who were treated with HCQ during 2014-2015. A questionnaire was used to collect data on the following demographic and clinical factors: age, gender, type of rheumatic disease, history of cataract surgery, daily and cumulative HCQ dose, and duration of HCQ use. Retinal toxicity was diagnosed on the basis of the automated perimetry results of the central 10° of vision and spectral domain optical coherence tomography. The associations between the demographic and clinical factors and retinal toxicity were assessed, and P < 0.05 was considered statistically significant. Retinal toxicity was detected in 18 (30.5%) of the patients, and 5 (8.5 %) developed color vision impairments. There was no association between retinal toxicity and sex (P = 0.514), history of cataract surgery (P = 0.479), type of rheumatic disease (P = 0.539), or daily HCQ dose (P = 0.062). However, there was a significant positive association between retinal toxicity and age (P = 0.006), cumulative HCQ dose (P = 0.002), and duration of HCQ use (P < 0.001). In conclusion, the risk factors for retinal toxicity after HCQ treatment were advanced age, use of a higher cumulative HCQ dose, and a longer duration of treatment.

Keywords: Autoimmune disease; Automated Perimetry; Hydroxychloroquine; Retinal Toxicity

Conflict of interest statement

None declared. No funding or sponsorship was received for this study. All the aforementioned authors met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this

References

  1. Clin Ophthalmol. 2015 Aug 20;9:1499-509 - PubMed
  2. Arthritis Rheum. 1990 Oct;33(10):1449-61 - PubMed
  3. Graefes Arch Clin Exp Ophthalmol. 1996 Jun;234(6):378-81 - PubMed
  4. Clin Genet. 1987 Apr;31(4):255-64 - PubMed
  5. Clin Rheumatol. 2013 Jun;32(6):895-8 - PubMed
  6. Br J Ophthalmol. 2005 May;89(5):521-2 - PubMed
  7. Acta Ophthalmol (Copenh). 1990 Apr;68(2):125-30 - PubMed
  8. Eye (Lond). 2010 Feb;24(2):340-6 - PubMed
  9. Eye (Lond). 2010 May;24(5):756-62; quiz 763 - PubMed
  10. BMC Med. 2010 Nov 29;8:77 - PubMed
  11. Clin Ophthalmol. 2015 May 27;9:943-52 - PubMed
  12. JAMA Ophthalmol. 2014 Dec;132(12):1453-60 - PubMed
  13. Ophthalmology. 2011 Feb;118(2):415-22 - PubMed
  14. Clin Ophthalmol. 2012;6:377-83 - PubMed
  15. Glob J Health Sci. 2015 Jun 25;8(3):59-64 - PubMed
  16. Trans Am Ophthalmol Soc. 2007;105:191-4; discussion 195-7 - PubMed
  17. Pol Merkur Lekarski. 2016 Apr;40(238):269-72 - PubMed
  18. Arthritis Care Res (Hoboken). 2010 Jun;62(6):775-84 - PubMed
  19. Reumatol Clin. 2013 Sep-Oct;9(5):259-62 - PubMed
  20. Ophthalmic Epidemiol. 2008 Jul-Aug;15(4):279-81 - PubMed

Publication Types